Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-Severe psoriasis.

Mark LebwohlAhmed M SolimanHongbo YangJessie WangJonathan FreimarkLluis Puig

Published in: The Journal of dermatological treatment (2021)

Higher PASI responses were associated with reduced TWPI. Risankizumab was associated with less work impairment/indirect costs versus ustekinumab/adalimumab/placebo.

Keyphrases

rheumatoid arthritis
climate change
high intensity
early onset
juvenile idiopathic arthritis
double blind
clinical trial
phase iii
systemic lupus erythematosus